Precision medicine

#Institute of Cancer Research #Oncology #Precision medicine

Combining precision medicines can treat drug-resistant cancers

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together… Read More

#Trending News

#DNAGenotek #Metabolomics #Metabolon #Precision medicine

Why metabolomics has the potential to transform diagnosis and treatment

Lu Rahman speaks to key members of Metabolon on the company’s pioneering work in metabolomics including its innovative collaborations with DNAGenotek and the Institute for Systems Biology. “Metabolon has built an unrivalled global biochemical profiling platform capable of providing metabolite data of unsurpassed quality and coverage,” says Brian Keppler, PhD, Director,… Read More

#Exclusive Content #Opinion

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology / Virology & Vaccines #Molecular medicine #Precision medicine #Preclinical #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

New manufacturing technologies make the promise of stem cell therapies a reality

By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More

#Business & Investment #Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Collaborative Research Leads To New Understanding Of Biomarkers

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell therapy #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Oncology #Pathology #Precision medicine #RNA #Screening #Stem cells #Therapeutics

Researchers discover cell communication mechanism that drives cancer adaptation

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins,… Read More

#Cancer Research #Covid-19 #News

#AI / data analytics / healthtech / informatics #Business #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Molecular medicine #Orphan drugs #Precision medicine

Centogene and Molecular Health collaborate to develop orphan drugs

Image: Fabio Centogene and Molecular Health, are to collaborate on the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project, starting with epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Genomics #Lead discovery #Precision medicine #Protein chemistry / Proteomics

Biopharma R&D interest in quantum computing due to efficiency and effectiveness benefits

27 July 2020 Image: Michael Dziedzic New survey results from the Pistoia Alliance, the Quantum Economic Development Consortium (QED-C) and QuPharm show almost one third of life science organisations polled are set to begin quantum computing evaluation this year. A further 39% are planning to evaluate next year… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Precision medicine #Preclinical #RNA #Therapeutics #Translational #Translational chemistry

Cancer vaccine shows promising signs

The Translational Research Institute-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug discovery #Gene therapy #Imaging #Lead discovery #Precision medicine #RNA

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection

Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care. In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Precision medicine #RNA

Symbiosis to manufacture COVID-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial… Read More

#Covid-19 #News